1.85
+0.082(+4.63%)
Currency In USD
| Previous Close | 1.77 |
| Open | 1.72 |
| Day High | 1.88 |
| Day Low | 1.72 |
| 52-Week High | 75.8 |
| 52-Week Low | 1.52 |
| Volume | 24,897 |
| Average Volume | 47,424 |
| Market Cap | 4.56M |
| PE | -0.11 |
| EPS | -17.23 |
| Moving Average 50 Days | 2.23 |
| Moving Average 200 Days | 8.61 |
| Change | 0.08 |
If you invested $1000 in Autonomix Medical, Inc. Common Stock (AMIX) since IPO date, it would be worth $18.26 as of April 19, 2025 at a share price of $1.852. Whereas If you bought $1000 worth of Autonomix Medical, Inc. Common Stock (AMIX) shares 6 months ago, it would be worth $179.46 as of April 19, 2025 at a share price of $1.852.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Autonomix Medical, Inc. Granted New European Patent for Proprietary Catheter-Based Technology
GlobeNewswire Inc.
Apr 16, 2025 12:30 PM GMT
New patent underscores breadth of application and expansion opportunities for Company’s catheter-based technology Continued progress with growing global patent portfolio to over 80 issued patents and 40 pending patent applications THE WOODLANDS, TX,
Autonomix Medical, Inc. Engages Leading Medical Experts to Guide U.S. Clinical and Regulatory Path in Pancreatic Cancer Pain
GlobeNewswire Inc.
Apr 08, 2025 12:15 PM GMT
Company on track to commence U.S. clinical studies in 2025 to support a De Novo application for FDA approval THE WOODLANDS, TX, April 08, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical devi
Autonomix Medical, Inc. to Highlight Technology and Early Proof-of-Concept Study Results in a Poster Presentation at the 2025 European Conference on Interventional Oncology (ECIO)
GlobeNewswire Inc.
Apr 03, 2025 12:30 PM GMT
THE WOODLANDS, TX, April 03, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing precision nerve-targeted treatments, today announced an abstract detailing it
Data not available